GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » 14-Day RSI

Immutep (ASX:IMM) 14-Day RSI

: 39.12 (As of Today)
View and export this data going back to 1988. Start your Free Trial

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-04-19), Immutep's 14-Day RSI is 39.12.

The industry rank for Immutep's 14-Day RSI or its related term are showing as below:

ASX:IMM's 14-Day RSI is ranked better than
59.47% of 1574 companies
in the Biotechnology industry
Industry Median: 41.595 vs ASX:IMM: 39.12

Competitive Comparison

For the Biotechnology subindustry, Immutep's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immutep 14-Day RSI Distribution

For the Biotechnology industry and Healthcare sector, Immutep's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where Immutep's 14-Day RSI falls into.



Immutep  (ASX:IMM) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Immutep  (ASX:IMM) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


Immutep 14-Day RSI Related Terms

Thank you for viewing the detailed overview of Immutep's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


Immutep (ASX:IMM) Business Description

Traded in Other Exchanges
Address
264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines